Mark Mendonça
Impact in
- Hematology top 10%
- Multiple Myeloma Research and Treatments
-
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
Papers in
- Oncology 7
- CAR-T cell therapy research 5
- Peptidase Inhibition and Analysis 2
-
- Multiple Myeloma Research and Treatments 4
- Acute Myeloid Leukemia Research 1
- Co-authors
- François Gaudet (4 shared papers)Ricardo M. Attar (4 shared papers)Kathryn Packman (3 shared papers)Yusri Elsayed (4 shared papers)Diana Chin (5 shared papers)Laurence C. Eisenlohr (2 shared papers)Yingzhe Li (3 shared papers)Alexander Babich (3 shared papers)
- Journals
- Blood (5 papers)Blood Advances (2 papers)Nature Medicine (1 paper)The Journal of Immunology (1 paper)Cancer Research (1 paper)
- Partner nations
- United StatesSwitzerlandIndia
In The Last Decade
Mark Mendonça
11 papers receiving 371 citations
Peers
Comparison fields: 5 of 43
- Hematology 138
- Oncology 195
- Immunology 134
- Radiology, Nuclear Medicine and Imaging 122
- Virology 17
Countries citing papers authored by Mark Mendonça
This map shows the geographic impact of Mark Mendonça's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Mendonça with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Mendonça more than expected).
Fields of papers citing papers by Mark Mendonça
This network shows the impact of papers produced by Mark Mendonça. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Mendonça. The network helps show where Mark Mendonça may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Mendonça, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 124 | |
| 2 | 2020 | 95 | |
| 3 | 2015 | 60 | |
| 4 | 2020 | 37 | |
| 5 | 2021 | 20 | |
| 6 | 2018 | 12 | |
| 7 | 2019 | 9 | |
| 8 | 2016 | 8 | |
| 9 | 2021 | 7 | |
| 10 | 2024 | 3 | |
| 11 | 2012 | 2 |
About Mark Mendonça
Mark Mendonça is a scholar working on Oncology, Hematology, Molecular Biology, Radiology, Nuclear Medicine and Imaging and Immunology, having authored 11 papers that have together received 377 indexed citations. Recurring topics across this work include CAR-T cell therapy research (5 papers), Multiple Myeloma Research and Treatments (4 papers), Immunotherapy and Immune Responses (3 papers), Monoclonal and Polyclonal Antibodies Research (3 papers), Peptidase Inhibition and Analysis (2 papers), Acute Myeloid Leukemia Research (1 paper), Microbial Inactivation Methods (1 paper) and Poxvirus research and outbreaks (1 paper). The work is most often cited by research in Hematology (138 citations), Oncology (195 citations), Immunology (134 citations), Radiology, Nuclear Medicine and Imaging (122 citations) and Virology (17 citations). Mark Mendonça has collaborated with scholars based in United States, Switzerland and India. Frequent co-authors include François Gaudet, Ricardo M. Attar, Kathryn Packman, Yusri Elsayed, Diana Chin, Laurence C. Eisenlohr, Yingzhe Li, Alexander Babich, Leopoldo Luistro and Kodandaram Pillarisetti. Their work appears in journals such as Blood, Blood Advances, Nature Medicine, The Journal of Immunology and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.